Neupulse®
Neupulse (Neurotherapeutics Solutions Ltd) is a pioneering medical-technology company dedicated to improving the lives of people with Tourette Syndrome and tic disorders.
Wearable Technology
Faculty of Medicine and Health Science / Faculty of Science
Profile
Neupulse® is a pioneering medical-technology company dedicated to improving the lives of people with Tourette Syndrome and tic disorders. Spun out from the University of Nottingham in 2021, it was founded by Professors Stephen and Georgina Jackson and Dr Barbara Morera with the goal of creating a non-invasive, drug-free treatment for Tourette’s Syndrome. This work has led to the development of the first wearable neuromodulation device designed specifically to reduce tics.
At the heart of Neupulse® is a simple mission – to empower individuals with Tourette’s Syndrome through practical, science-driven innovation. Its wrist-worn device, controlled via a mobile app, delivers gentle stimulation to help manage tics. In a UK clinical trial, participants experienced reductions in tic frequency of more than 25% and decreases in tic severity of around 35%.
Neupulse® aims to support individuals, families and healthcare professionals seeking effective, non-invasive solutions. With a UK launch in 2026, the company remains focused on advancing neuromodulation science and building a supportive community for those who need it most.